The Impact of Previous Comorbidities on New Comorbidities and Medications after a Mild SARS-CoV-2 Infection in a Lithuanian Cohort
This cross-sectional study investigates new comorbidities and new medications after a mild SARS-CoV-2 infection. Data were collected after an acute SARS-CoV-2 infection by online survey in a Lithuanian cohort. Sociodemographic data, SARS-CoV-2-related symptoms, previous and new comorbidities, and me...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2024-01-01
|
| Series: | Journal of Clinical Medicine |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2077-0383/13/2/623 |
| _version_ | 1797339700336263168 |
|---|---|
| author | Dovilė Važgėlienė Raimondas Kubilius Indre Bileviciute-Ljungar |
| author_facet | Dovilė Važgėlienė Raimondas Kubilius Indre Bileviciute-Ljungar |
| author_sort | Dovilė Važgėlienė |
| collection | DOAJ |
| description | This cross-sectional study investigates new comorbidities and new medications after a mild SARS-CoV-2 infection. Data were collected after an acute SARS-CoV-2 infection by online survey in a Lithuanian cohort. Sociodemographic data, SARS-CoV-2-related symptoms, previous and new comorbidities, and medications were analysed. The results of 895 participants (mean age: 44 years) show that 91% were women, 58% had higher education, and 84% were working. Among those, 473 (52.8%) answered being “healthy” before infection; 823 (92%) indicated being positive on diagnostic tests; and 841 (94%) were non-hospitalized. Asymptomatic infection was reported by 17 participants (1.9%). Participants reporting any comorbidity before a SARS-CoV-2 infection reported more frequently having remaining symptoms compared to those who were “healthy”, particularly in relation to neurological symptoms. Thirteen percent of participants reported new comorbidities, and thirty-five percent started new medication. Among new medications, an intake of vitamins/supplements (21%) and anti-inflammatory drugs (4%) was more often reported by “unhealthy” participants. Regression analysis revealed that new cardiovascular and pulmonary diagnoses predicted each other. Participants reporting prior neurological disorders tended to have an increased risk of intaking new vitamins/supplements and anti-inflammatory drugs after infection. The results indicate a significantly increased consumption of medication, particularly unprescribed substances, after SARS-CoV-2, indicating a need of more research in this area. |
| first_indexed | 2024-03-08T09:51:09Z |
| format | Article |
| id | doaj.art-ac8b05b229164b14b67014599b195864 |
| institution | Directory Open Access Journal |
| issn | 2077-0383 |
| language | English |
| last_indexed | 2024-03-08T09:51:09Z |
| publishDate | 2024-01-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Journal of Clinical Medicine |
| spelling | doaj.art-ac8b05b229164b14b67014599b1958642024-01-29T14:03:51ZengMDPI AGJournal of Clinical Medicine2077-03832024-01-0113262310.3390/jcm13020623The Impact of Previous Comorbidities on New Comorbidities and Medications after a Mild SARS-CoV-2 Infection in a Lithuanian CohortDovilė Važgėlienė0Raimondas Kubilius1Indre Bileviciute-Ljungar2Department of Physical Rehabilitation Medicine, Kaunas Clinic of the Lithuanian University of Health Sciences, 50161 Kaunas, LithuaniaDepartment of Physical Rehabilitation Medicine, Kaunas Clinic of the Lithuanian University of Health Sciences, 50161 Kaunas, LithuaniaDepartment of Clinical Sciences, Karolinska Institute, Danderyd University Hospital, 182 57 Stockholm, SwedenThis cross-sectional study investigates new comorbidities and new medications after a mild SARS-CoV-2 infection. Data were collected after an acute SARS-CoV-2 infection by online survey in a Lithuanian cohort. Sociodemographic data, SARS-CoV-2-related symptoms, previous and new comorbidities, and medications were analysed. The results of 895 participants (mean age: 44 years) show that 91% were women, 58% had higher education, and 84% were working. Among those, 473 (52.8%) answered being “healthy” before infection; 823 (92%) indicated being positive on diagnostic tests; and 841 (94%) were non-hospitalized. Asymptomatic infection was reported by 17 participants (1.9%). Participants reporting any comorbidity before a SARS-CoV-2 infection reported more frequently having remaining symptoms compared to those who were “healthy”, particularly in relation to neurological symptoms. Thirteen percent of participants reported new comorbidities, and thirty-five percent started new medication. Among new medications, an intake of vitamins/supplements (21%) and anti-inflammatory drugs (4%) was more often reported by “unhealthy” participants. Regression analysis revealed that new cardiovascular and pulmonary diagnoses predicted each other. Participants reporting prior neurological disorders tended to have an increased risk of intaking new vitamins/supplements and anti-inflammatory drugs after infection. The results indicate a significantly increased consumption of medication, particularly unprescribed substances, after SARS-CoV-2, indicating a need of more research in this area.https://www.mdpi.com/2077-0383/13/2/623SARS-CoV-2 virusmedicationcomorbiditiespost-COVID-19 conditionvitamins/supplements |
| spellingShingle | Dovilė Važgėlienė Raimondas Kubilius Indre Bileviciute-Ljungar The Impact of Previous Comorbidities on New Comorbidities and Medications after a Mild SARS-CoV-2 Infection in a Lithuanian Cohort Journal of Clinical Medicine SARS-CoV-2 virus medication comorbidities post-COVID-19 condition vitamins/supplements |
| title | The Impact of Previous Comorbidities on New Comorbidities and Medications after a Mild SARS-CoV-2 Infection in a Lithuanian Cohort |
| title_full | The Impact of Previous Comorbidities on New Comorbidities and Medications after a Mild SARS-CoV-2 Infection in a Lithuanian Cohort |
| title_fullStr | The Impact of Previous Comorbidities on New Comorbidities and Medications after a Mild SARS-CoV-2 Infection in a Lithuanian Cohort |
| title_full_unstemmed | The Impact of Previous Comorbidities on New Comorbidities and Medications after a Mild SARS-CoV-2 Infection in a Lithuanian Cohort |
| title_short | The Impact of Previous Comorbidities on New Comorbidities and Medications after a Mild SARS-CoV-2 Infection in a Lithuanian Cohort |
| title_sort | impact of previous comorbidities on new comorbidities and medications after a mild sars cov 2 infection in a lithuanian cohort |
| topic | SARS-CoV-2 virus medication comorbidities post-COVID-19 condition vitamins/supplements |
| url | https://www.mdpi.com/2077-0383/13/2/623 |
| work_keys_str_mv | AT dovilevazgeliene theimpactofpreviouscomorbiditiesonnewcomorbiditiesandmedicationsafteramildsarscov2infectioninalithuaniancohort AT raimondaskubilius theimpactofpreviouscomorbiditiesonnewcomorbiditiesandmedicationsafteramildsarscov2infectioninalithuaniancohort AT indrebileviciuteljungar theimpactofpreviouscomorbiditiesonnewcomorbiditiesandmedicationsafteramildsarscov2infectioninalithuaniancohort AT dovilevazgeliene impactofpreviouscomorbiditiesonnewcomorbiditiesandmedicationsafteramildsarscov2infectioninalithuaniancohort AT raimondaskubilius impactofpreviouscomorbiditiesonnewcomorbiditiesandmedicationsafteramildsarscov2infectioninalithuaniancohort AT indrebileviciuteljungar impactofpreviouscomorbiditiesonnewcomorbiditiesandmedicationsafteramildsarscov2infectioninalithuaniancohort |